Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$1.81 -11.7%	$3.08	$1.78 ▼ $17.31	$44.10M	N/A	174,105 shs	165,594 shs
MRKR Marker Therapeutics	$1.12 -1.8%	$1.19	$0.95 ▼ $5.99	$12.67M	1.29	62,458 shs	60,856 shs
OTLK Outlook Therapeutics	$1.75 -13.8%	$1.43	$0.87 ▼ $9.25	$56.03M	0.39	748,817 shs	932,439 shs
RENB Renovaro	$0.33 -1.6%	$0.50	$0.29 ▼ $2.34	$52.38M	0.62	965,733 shs	1.75 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-2.38%	+8.18%	+3.54%	-44.29%	+204,999,900.00%
MRKR Marker Therapeutics	0.00%	0.00%	+10.68%	-28.30%	-72.13%
OTLK Outlook Therapeutics	+27.67%	+41.96%	+47.10%	+16.67%	-73.08%
RENB Renovaro	+3.71%	+15.51%	-11.09%	-53.34%	-71.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	1.9594 of 5 stars	3.5	0.0	0.0	1.8	1.7	0.6
MRKR Marker Therapeutics	4.4758 of 5 stars	3.8	5.0	3.9	3.3	0.8	0.6
OTLK Outlook Therapeutics	1.7963 of 5 stars	3.4	3.0	0.0	1.9	0.0	0.6
RENB Renovaro	0.8634 of 5 stars	0.0	2.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$20.40	1,027.07% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	1,075.60% Upside
OTLK Outlook Therapeutics	2.80	Moderate Buy	$10.20	482.86% Upside
RENB Renovaro	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRKR, RENB, ARTV, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/26/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $20.00
3/25/2025	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00 ➝ $18.00
3/25/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/5/2025	MRKR Marker Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
2/24/2025	OTLK Outlook Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $24.00
2/18/2025	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
2/18/2025	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $3.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$251K	175.69	N/A	N/A	N/A	∞
MRKR Marker Therapeutics	$6.59M	1.92	N/A	N/A	$1.58 per share	0.71
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.57) per share	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/23/2025 (Estimated)
MRKR Marker Therapeutics	-$8.24M	-$1.20	N/A	N/A	N/A	-179.74%	-89.63%	-71.62%	5/21/2025 (Estimated)
OTLK Outlook Therapeutics	-$75.37M	-$7.42	N/A	N/A	N/A	N/A	N/A	-225.12%	5/21/2025 (Estimated)
RENB Renovaro	-$80.65M	-$0.93	N/A	∞	N/A	N/A	-61.84%	-48.07%	5/14/2025 (Estimated)

Latest MRKR, RENB, ARTV, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MRKR Marker Therapeutics	-$0.66	N/A	N/A	N/A	$0.50 million	N/A
5/21/2025	Q2 2025	OTLK Outlook Therapeutics	-$0.55	N/A	N/A	N/A	$0.70 million	N/A
5/8/2025	Q1 2025	ARTV Artiva Biotherapeutics	-$0.68	-$0.83	-$0.15	-$0.83	N/A	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million
2/19/2025	Q2 2025	RENB Renovaro	N/A	-$0.02	N/A	-$0.04	N/A	N/A
2/14/2025	Q1 2025	OTLK Outlook Therapeutics	-$0.85	-$0.89	-$0.04	$0.72	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	11.33	11.33
MRKR Marker Therapeutics	N/A	3.15	3.15
OTLK Outlook Therapeutics	N/A	0.32	0.64
RENB Renovaro	N/A	0.06	0.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
MRKR Marker Therapeutics	22.39%
OTLK Outlook Therapeutics	11.20%
RENB Renovaro	71.41%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
MRKR Marker Therapeutics	14.50%
OTLK Outlook Therapeutics	4.80%
RENB Renovaro	21.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.36 million	N/A	N/A
MRKR Marker Therapeutics	60	11.32 million	9.16 million	Not Optionable
OTLK Outlook Therapeutics	20	32.02 million	30.48 million	Optionable
RENB Renovaro	20	158.72 million	124.24 million	Optionable

MRKR, RENB, ARTV, and OTLK Headlines

Recent News About These Companies

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 14 at 9:15 AM | globenewswire.com

Renovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiek

May 13 at 7:33 PM | nl.investing.com

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

May 13 at 9:15 AM | globenewswire.com

Renovaro Inc. (NASDAQ:RENB) Shares Acquired by Geode Capital Management LLC

May 2, 2025 | marketbeat.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,32 door marktuitdagingen

May 1, 2025 | nl.investing.com

Renovaro BioSciences expands collaboration with Nebul

April 23, 2025 | markets.businessinsider.com

Renovaro Inc. Expands Collaboration with Nebul to Enhance Early Cancer Detection Through Advanced AI Technology

April 22, 2025 | quiverquant.com

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

April 22, 2025 | globenewswire.com

Renovaro riskeert Nasdaq-notering te verliezen door te lage aandelenkoers

April 18, 2025 | nl.investing.com

Renovaro BioSciences, BioSymetrics close merger transaction

April 9, 2025 | markets.businessinsider.com

Renovaro Inc: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

April 9, 2025 | finanznachrichten.de

Renovaro fuseert met BioSymetrics voor AI-gedreven medicijnontwikkeling

April 9, 2025 | nl.investing.com

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

April 9, 2025 | globenewswire.com

Predictive Oncology Ends Merger Talks with Renovaro

April 7, 2025 | tipranks.com

Renovaro Biosciences stuit op tegenslag bij fusie met Predictive Oncology

April 6, 2025 | nl.investing.com

Renovaro Inc: Renovaro Provides Update to Definitive Agreement with Predictive Oncology

April 4, 2025 | finanznachrichten.de

Renovaro BioSciences provides update to agreement with Predictive Oncology

April 4, 2025 | markets.businessinsider.com

Renovaro Shares Fall After Merger Setback

April 4, 2025 | marketwatch.com

Renovaro says Predictive Oncology terminates merger transaction

April 4, 2025 | markets.businessinsider.com

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

April 4, 2025 | globenewswire.com

Renovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive Oncology

March 5, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, RENB, ARTV, and OTLK Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$1.81 -0.24 (-11.71%)

As of 04:00 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Marker Therapeutics NASDAQ:MRKR

$1.12 -0.02 (-1.75%)

As of 03:59 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Outlook Therapeutics NASDAQ:OTLK

$1.75 -0.28 (-13.79%)

As of 04:00 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Renovaro NASDAQ:RENB

$0.33 -0.01 (-1.55%)

As of 04:00 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time